WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...
A large-scale analysis of treatments for benign prostatic hyperplasia (BPH) showed that complications are lowest after the UroLift Prostatic Urethral Lift (PUL) procedure, and real-world retreatment ...
“Arriving at the intersection of effective BPH treatment, patient priorities and available technology can be a daunting task,” said Mr. Olly Kayes, MD, Honorary Senior Lecturer at the University of ...
WAYNE, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the publication of an article showcasing the effectiveness and overall benefits of the minimally ...
TEXARKANA, Texas — Benign prostatic hyperplasia — or BPH — is a common condition in men over 50 that causes the prostate to enlarge. The enlarged prostate pinches the urethra, which carries urine from ...
Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...
Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results